- Exchange: SIX Swiss Ex
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Basilea Pharmaceutica
+ Add to WatchlistBSLN:SW
68.45 CHF 0.30 0.44%As of 08:35:32 ET on 05/22/2013.
Snapshot for Basilea Pharmaceutica (BSLN)
| Open: | 68.95 | Day's Range: | 67.00 - 69.15 | Volume: | 57,400 |
|---|---|---|---|---|---|
| Previous Close: | 68.15 | 52wk Range: | 35.29 - 71.00 | 1-Yr Rtn: | +76.58% |
Key Statistics for BSLN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SMI | - |
| Earnings Per Share (CHF) (ttm) | -5.5300 |
| Est. EPS (CHF) (12/2013) | -4.1750 |
| Est. PEG Ratio | - |
| Market Cap (M CHF) | 652.08 |
| Shares Outstanding (M) | 9.59 |
| 30 Day Average Volume | 57,096 |
| Price/Book (mrq) | 6.2205 |
| Price/Sale (ttm) | 11.3380 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend (CHF) | 5.0000 |
| Last Dividend | 04/11/2013 |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/21/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for BSLN
Company Profile & Key Executives for BSLN
Basilea Pharmaceutica AG is a biotechnology company conducting research into the development of drugs for the treatment of infectious diseases and dermatological problems. The Company develops anti-bacterial and anti-fungal compounds which destroy infectious organisms.
| Martin NicklassonChairman | Domenico ScalaVice Chairman |
| Ronald Scott "Ron"CEO/Interim CFO | Ingrid Heinze-KraussChief Technology Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
BSLN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page